Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
暂无分享,去创建一个
N. Reinmuth | A. Bleckmann | M. Reck | M. Sebastian | F. Griesinger | J. Kollmeier | N. Frost | M. Janning | Michael Thomas | C. Grohé